

Ovoca Bio plc

("Ovoca" or the "Company")

Notice of AGM

Dublin, Ireland, November 7, 2023 - Ovoca Bio, a biopharmaceutical company with a focus on women's health, announces that a Notice of Annual General Meeting ("AGM"), containing details of the resolutions to be proposed at the AGM, has been published and posted to shareholders. The Notice of AGM is also available on the Company's website at <https://ovocabio.com/agm-registration/>.

The Company's 2023 AGM will be held via live conference facility on 30 November 2023 at 4 p.m. Further details in relation to shareholder participation in the meeting is detailed in the Notice of AGM.

It will be possible to fully participate in the meeting using the live conferencing facility provided by the Company for this purpose. Shareholders will be able to use this facility to vote and /or ask questions. Shareholders will also be able to submit questions in advance of the AGM in writing by email to the Company Secretary at info@ovocabio.com to be received no later than 4 p.m. on 28 November 2023. All correspondence should include sufficient information to identify the shareholder on the Register of Members. Questions submitted using these methods will be addressed by the Chairman at the AGM, where possible.

End

For further information:

Ovoca Bio plc

Kirill Golovanov (Chief Executive)

Tel +353 1 661 9819

info@ovocabio.com

Davy (Nominated Adviser, Euronext Growth Listing Sponsor and Broker)

Ivan Murphy / Daragh O'Reilly

Tel: +353 1 679 6363

About Ovoca Bio

Ovoca Bio is a European-based biopharmaceutical company with a focus on women's health. The Company is currently developing Orenetide (BP-101), a novel synthetic peptide administered through a nasal spray as a novel treatment for women with hypoactive sexual desire disorder (HSDD), a condition characterized by a distressing lack or loss of sexual desire affecting an estimated ~4 million premenopausal women in the US alone.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

